SKINGENUITY® Vaginal Rejuvenation

SKINGENUITY® Vaginal Regenerative Gel

SKINGENUITY® Vaginal RegenerativeGel (SKINGENUITY® VR) aims to be the first line treatment for Vaginal Rejuvenation using our patent pending technology.

SKINGENUITY® VR Gel can be used to help with the symptoms of Vaginal Laxity, Genitourinary Symptoms of Menopause (GSM) as well as being used in combination with Laser Vaginal Rejuvenation.

SKINGENUITY® VR Gel has been clinically tested and was found to have a significant improvement in the main measures of vaginal health as defined in the Vaginal Health Index1.

The aim of any Vaginal Rejuvenation treatment is to help improve the vaginal lining, which has been thinned mainly due to a change in estrogen levels post menopause.

The term Vaginal Rejuvenation has been used extensively in the media and generally to describe any aesthetic treatment related to the Vagina. The treatments that are on offer are used to treat Genitourinary Syndrome of Menopause (GSM). GSM is a new term that describes various menopausal symptoms and signs including not only genital symptoms (dryness, burning, and irritation), and sexual symptoms (lack of lubrication, discomfort or pain, and impaired function, but also urinary symptoms (urgency, dysuria, and recurrent urinary tract infections) which are a consequence of aging, particularly after menopause. GSM can significantly affect a patient’s quality of life and is common

among women who have been through the menopause with report of up to 45% of post-menopausal women whose quality of life has been negatively impacted1.

Intermediate and superficial cells predominate in premenopausal women minimal parabasal cells.

After menopause, there is an increase in Parabasal and intermediate cells and a substantial decrease in puperficial cells.

Current Treatment

There are several treatments available to help improve the symptoms of GSM and they vary from creams, replacing the estogen which are only available on prescription to the use of CO2 lasers which use a probe inserted in the vagina to help improve the symptoms.

Current treatments can cause trauma to the mucosal lining of the vagina or with oestrogen creams, can have significant risks associated with them.

None of the treatments are ideal and an easy to use treatment that has been clinically proven to help improve the symptoms of GSM would help patients significantly.

SKINGENUITY® VR Gel improves the symptoms of GSM?

SKINGENUITY® VR Gel has been clinically tested and was found to have a significant improvement in the main measures of vaginal health as defined in the Vaginal Health Index2. The Vaginal Health Index (VHI) is a system used to evaluate vaginal elasticity, fluid volume, pH, epithelial integrity, and moisture on a scale of 1 to 5.

Pre-Treatment:
Dense and disorganized Collagen and atrophy:

post treatment with skingenuity®
Epithelium with several layers of cells of tromal maturation with an increase of collagen.

Biopsy of Vaginal Lining pre and post-treatment with SKINGENUITY® VR Gel

Overall, the patients in the clinical study were satisfied with the treatment and the outcome which they believed improved their symptoms.

All subjects reported an important cosmetic improvement in labia majora and perineal area. There were no side effects reported by the patient group.

How does SKINGENUITY® VR Gel work?

SKINGENUITY® VR Gel can be used to help with the symptoms of Vaginal Laxity, Genitourinary Symptoms of Menopause (GSM) as well as being used in combination with Laser Vaginal Rejuvenation.

SKINGENUITY® VR Gel contains focussed and targeted Growth Factors that are nano-encapsulated to ensure penetration into the vaginal mucosal lining.

SKINGENUITY® VR Gel has been proven quantitatively in Clinical Trials to significantly improve the main symptoms of GSM.

The Growth Factors have all been proven to help improve the atrophy of the vaginal lining.

SKINGENUITY® VR – Application Frequency:

SKINGENUITY^®VR can be used alone or as post-procedure treatment. Apply 2-3 times weekly.
If the desired results have been obtained, decrease use to 2-3 times monthly for long-term benefits.
Apply SKINGENUITY^®VR before going to bed in order to maximize the effect.
There is no contraindication to sexual activity. If there is sexual activity, apply SKINGENUITY^® VR afterwards.
There are no contraceptive ingredients in SKINGENUITY^® VR, continue using contraceptives.
If there is any discomfort then stop the treatment and consult your Physician or Healthcare Provider.

References:

[1] Cardozo L, Bachmann G, McClish D, Fonda D, Birgerson L. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 1998;92: 722–7

[2] Cardozo L, Bachmann G, McClish D, Fonda D, Birgerson L. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 1998;92: 722–7